BCL2L1 and acute myeloid leukemia: Ofthese agents, ABT-737, a BH3 mimetic that antagonizes BCL-2, BCL-XL, andBCL-w, demonstrated remarkable single-agent efficacy against AML in preclinicalstudies2.